← Back to Screener
Novartis AG (NVS)
Price$150.99
Favorite Metrics
Price vs S&P 500 (26W)2.13%
Price vs S&P 500 (4W)-7.23%
Market Capitalization$214.36B
P/E Ratio (Annual)19.61x
Indicated Dividend Yield (Annual)3.11%
All Metrics
P/CF (Annual)14.32x
Book Value / Share (Quarterly)$24.04
P/TBV (Annual)15.96x
Indicated Dividend (Annual)$3.50
Revenue Growth (3Y)9.10%
Cash Flow / Share (Quarterly)$7.94
Payout Ratio (TTM)102.24%
Price vs S&P 500 (YTD)4.50%
Gross Margin (TTM)75.82%
Net Profit Margin (TTM)24.83%
EPS (TTM)$7.16
10-Day Avg Trading Volume2.40M
EPS Excl Extra (TTM)$7.16
Revenue Growth (5Y)2.45%
EPS (Annual)$7.15
Dividend / Share (Annual)$4.02
ROI (Annual)17.16%
Gross Margin (Annual)75.82%
Net Profit Margin (5Y Avg)30.08%
Cash / Share (Quarterly)$6.04
P/E Basic Excl Extra (TTM)19.61x
Revenue Growth QoQ (YoY)2.23%
EPS Growth (5Y)15.26%
P/E Normalized (Annual)19.61x
ROA (Last FY)12.60%
Revenue Growth TTM (YoY)8.91%
EBITD / Share (TTM)$9.15
ROE (5Y Avg)27.29%
Operating Margin (TTM)31.00%
Cash Flow / Share (Annual)$7.94
P/B Ratio5.94x
P/B Ratio (Quarterly)5.78x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)5.29x
Net Interest Coverage (TTM)15.76x
ROA (TTM)13.24%
EPS Growth QoQ (YoY)-11.02%
EV / EBITDA (TTM)16.70x
EPS Incl Extra (Annual)$7.15
Current Ratio (Annual)1.12x
Quick Ratio (Quarterly)0.89x
3-Month Avg Trading Volume3.20M
52-Week Price Return9.24%
EV / Free Cash Flow (Annual)19.56x
P/E Incl Extra (TTM)19.61x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$8.71
P/S Ratio (Annual)4.87x
Asset Turnover (Annual)0.51x
52-Week High$131.00
Operating Margin (5Y Avg)23.98%
EPS Excl Extra (Annual)$7.15
CapEx CAGR (5Y)8.57%
Tangible BV CAGR (5Y)-3.32%
26-Week Price Return10.88%
Quick Ratio (Annual)0.89x
13-Week Price Return2.27%
Total Debt / Equity (Annual)0.77x
Current Ratio (Quarterly)1.12x
Enterprise Value$298,167.123
Revenue / Share Growth (5Y)5.80%
Asset Turnover (TTM)0.53x
Book Value / Share Growth (5Y)-0.84%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.27x
Pretax Margin (Annual)29.03%
Cash / Share (Annual)$6.04
3-Month Return Std Dev19.14%
Gross Margin (5Y Avg)74.71%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)12.85%
EBITDA Interim CAGR (5Y)6.82%
ROE (Last FY)30.31%
Net Interest Coverage (Annual)15.76x
EPS Basic Excl Extra (Annual)$7.15
P/FCF (TTM)17.99x
Receivables Turnover (TTM)6.89x
EV / Free Cash Flow (TTM)19.56x
Total Debt / Equity (Quarterly)0.77x
EPS Incl Extra (TTM)$7.16
Receivables Turnover (Annual)6.89x
ROI (TTM)18.54%
Dividend Growth Rate (5Y)5.38%
P/S Ratio (TTM)4.87x
Pretax Margin (5Y Avg)29.46%
Revenue / Share (Annual)$28.81
Tangible BV / Share (Annual)$8.71
Forward P/E17.25x
Free OCF CAGR (5Y)6.62%
Price vs S&P 500 (52W)12.75%
P/E Ratio (TTM)19.61x
EPS Growth TTM (YoY)21.92%
Year-to-Date Return7.87%
5-Day Price Return-1.71%
EPS Normalized (Annual)$7.15
ROA (5Y Avg)12.66%
Net Profit Margin (Annual)24.83%
Month-to-Date Return-2.18%
Cash Flow / Share (TTM)$6.56
EBITD / Share (Annual)$9.13
EPS Growth (3Y)31.22%
Operating Margin (Annual)31.00%
LT Debt / Equity (Annual)0.61x
P/CF (TTM)14.32x
ROI (5Y Avg)17.13%
P/E Excl Extra (TTM)19.61x
LT Debt / Equity (Quarterly)0.61x
EPS Basic Excl Extra (TTM)$7.16
P/TBV (Quarterly)15.96x
Payout Ratio (Annual)55.91%
P/B Ratio (Annual)5.78x
Dividend / Share (TTM)$4.02
Inventory Turnover (TTM)2.27x
Pretax Margin (TTM)29.03%
Book Value / Share (Annual)$24.04
Price vs S&P 500 (13W)-0.60%
Net Margin Growth (5Y)8.94%
Dividend Yield (TTM)2.85%
Beta1.06x
P/FCF (Annual)17.99x
Revenue / Share (TTM)$29.20
ROE (TTM)32.75%
52-Week Low$87.89
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share) | 1.40x | 69.14% | 72.55% | -8.08% | $47.99 |
About
Novartis is a global pharmaceutical company specializing in innovative drug development across oncology, immunology, neuroscience, and respiratory/cardiovascular/metabolic diseases. It operates both an innovative medicines segment and an established medicines business with off-patent franchises. The U.S. accounts for approximately one-third of revenue, providing geographic diversification.